Enstilar in Combination With Enbrel or Humira for Plaque Psoriasis

Psoriasis Treatment Center of Central New Jersey

Status and phase: Enrolling; Phase 4

Conditions: Psoriasis

Treatments: Drug: Enstilar 0.005%-0.064% Topical Foam

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT03827876

PTC04

Details and patient eligibility

About

4 weeks of adjunctive therapy of Enstilar® QD followed by 12 weeks QOD to patients with 2-10% BSA who are receiving etanercept or adalimumab for at least 24 weeks

Full description

30 subjects treated with etanercept or adalimumab for at least 24 weeks with a body surface area 2-10% and physician global assessment greater than or equal to 2 will receive Enstilar® once daily for 4 weeks followed by QOD for 12 weeks.

Enrollment: 30 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male or female adult ≥ 18 years of age;
• Diagnosis of chronic plaque-type
• Patient with 2-10% BSA
• Physician Global Assessment of 2 or greater
• Patient has been treated with etanercept or adalimumab for a minimum of 24 weeks

Exclusion criteria

• ˂2 or >10% BSA
• PGA <2
• Patient not receiving etanercept or adalimumab, or receiving etanercept or adalimumab <24weeks

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

30 participants in 1 patient group

Open Label Enstilar

Experimental group

Description:

once daily for 4 weeks followed by QOD for 12 weeks for patients receiving Enbrel or Humira

Treatment:

Drug: Enstilar 0.005%-0.064% Topical Foam